340B Recertification for Hospitals Starts Aug. 14

HRSA hospital recertification.
HRSA announced this year's 340B eligibility recertification period for hospitals will start Aug. 14 and end Sept. 11.
This year’s 340B eligibility recertification period for hospitals will start Aug. 14 and end Sept. 11, the U.S. Health Resources [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Amgen, Vertex, and AstraZeneca Post 340B Refund and Replenishment Public Notices

Aranesp
Aranesp is among the drugs listed on HRSA's latest manufacturer's notice posted on behalf of Amgen.
The U.S. Health Resources and Services Administration (HRSA) this week published notices from drug makers Amgen and Vertex about refunds [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Report Publisher and CEO to Providers: New 340B Reporting Requirements are Inevitable

Tim Walz
Minnesota became the first state to impose 340B reporting requirements after Gov. Tim Walz (D) signed legislation in late May.
Health care providers almost certainly will have to accept new 340B reporting requirements in order to get unfettered access to [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B INDUSTRY LEADER SPOTLIGHT

Tracy Jones, Midwest Regional Director & National Director of Advocacy, AIDS Healthcare Foundation

Tracy Jones
Tracy Jones

Q: Where did you grow up?

I grew up on the Eastside of Cleveland, Ohio in the inner city.

Q: Where did you go to college/graduate school?

I went to Kent State University and Case Western University for grad school.

Q: What are your favorites?

Food: Red Velvet Cheesecake

Movie: The Color Purple

Musicians: Marvin Gaye, Prince

Read More »

Exclusive

Large Drug Maker, Big Health System, and Influential Health Center Jointly Lobbying for Senate Bipartisan 340B Initiative

340B Working Table 340B lobbying disclosure form
Under the name 340B Working Table, Genentech, Sanford Health, and Carolina Health Centers are jointly lobbying for a bipartisan U.S. Senate 340B reform initiative.

Biopharmaceutical manufacturer Genentech, South Dakota-based health system Sanford Health, and South Carolina federally qualified health center Carolina Health Centers are jointly lobbying members of Congress to back six U.S. senators’ bipartisan approach to federal 340B program reform, the three organizations

Read More »

Senate Panel Seems to Be on Track To Vote Tomorrow on Bill With Language that 340B Providers Oppose

Ron Wyden and Mike Crapo
Sens. Ron Wyden (left) and Mike Crapo's final revised PBM reform bill appears to retain language that 340B provider groups oppose.
The U.S. Senate Finance Committee apparently remains on track to vote Wednesday on a pharmacy benefit manager reform bill with [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

RWC-340B Backs Senate Bill That Would Let Ryan White Clinics Cover HIV Prevention Drugs and Services

PrEP tablet
New U.S. Senate legislation would let Ryan White clinics voluntarily use federal grants for HIV prevention medications and associated services.
Ryan White Clinics for 340B Access (RWC-340B) last week praised a new bill in the U.S. Senate that would let [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

NACHC Names Prominent Physician with Health Center and HRSA Experience as its Leader

Dr. Kyu Rhee
NACHC has chosen Dr. Kyu Rhee, now CVS Health senior vice president and Aetna chief medical officer, to be its new president and CEO.
The National Association of Community Health Centers (NACHC) announced yesterday that its board has chosen Dr. Kyu Rhee, now CVS [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B May Cause Providers to Buy More Expensive HIV Prevention Drugs, Conservative Policy Group Says

American Action Forum
The American Action Forum says in a new paper that 340B incentivizes providers to favor more expensive HIV medications, "raising costs for the rest of the health care system."
The 340B drug pricing program may incentivize hospitals and other covered entities to buy expensive preventative HIV medications over low-cost [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Generic Drugmaker Amring Providing Refunds for 340B Overcharges

Generic drug manufacturer Amring Pharmaceuticals is giving 340B covered entities refunds for overcharges on 14 products between the first quarter [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live